A promising new horse vaccine may reignite enthusiasm for DNA vaccine technology in designing prophylactics against infectious disease. Kendall Powell reports.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
References
Wolff, J. et al. Science 247, 1465–1468 (1990).
Jiao, S. et al. Hum. Gen. Ther. 3, 21–33 (1992).
Whalen, R. Emerg. Infect. Dis. 2, 168–175 (1996).
Martin, T. et al. Hum. Gene Ther. 10, 759–768 (1999).
Sullivan, N.J. et al. Nature 408, 605–609 (2000).
Amara, R.R. et al. Science 292, 69–74 (2001).
Davis, B.S. et al. J. Virol. 75, 4040–4047 (2001).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Powell, K. DNA vaccines—back in the saddle again?. Nat Biotechnol 22, 799–801 (2004). https://doi.org/10.1038/nbt0704-799
Issue date:
DOI: https://doi.org/10.1038/nbt0704-799
This article is cited by
-
DNA vaccines: precision tools for activating effective immunity against cancer
Nature Reviews Cancer (2008)
-
Identification and characterization of IS1 transposition in plasmid amplification mutants of E. coli clones producing DNA vaccines
Applied Microbiology and Biotechnology (2006)
